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Serum anticapsular polysaccharide antibodies confer immunity to invasive diseases 
caused by Haemophdus  influenzae type b  (HIB) t  (1-10). These anti-type b  antibodies 
exert their protective effect by initiating complement-mediated activities including 
opsonization and bacterial lysis (2-5,  11). A protective level of ~0.15 #g of anti-type 
b antibodies/ml serum was estimated based upon analyses of patients with X-linked 
hypogammaglobulinemia who were passively immunized with immunoglobulin and 
on analyses of vaccinees injected with the purified HIB capsular polysaccharide (HIB 
Ps)  (6-8, 11-13). In two field trials the HIB Ps induced a protective immune response 
only in children older than 18-24 mo (6-8). Reinjection of the HIB Ps did not induce 
a  booster effect at any age (8,  13,  14). This age-related immunological behavior to 
HIB Ps in humans is similar to that observed with other purified bacterial capsular 
polysaccharides (14-17) and has been characterized as "thymic-independent" (12, 18, 
19). To achieve immunoprophylactic control of meningitis caused by HIB and other 
encapsulated bacteria,  a  more effective vaccine for infants,  perhaps  with  "thymic- 
dependent" properties, must be developed. 
Goebel  (20)  and  Avery and  Goebel  (21,  22)  prepared  protein  conjugates of the 
pneumococcus type 3  polysaccharide as  well  as  of its  repeating  dissacharide  unit, 
cellobiuronic acid.  In  contrast  to the  poor immunogenicity of the  purified type 3 
polysaccharide in rabbits, these protein-carbohydrate conjugates induced high levels 
of serum antibodies that increased in concentration with reinjection and were protec- 
tive against  challenge with  the  live organisms  (23,  24).  Other  investigators,  using 
carbohydrates derived  from  pathogenic bacteria,  have  prepared  covalently bound 
conjugates with proteins, noncovalently bound protein-polysaccharide complexes, or 
polysaccharide-erythrocyte conjugates. These products revealed enhanced immuno- 
genicity of the carbohydrate moiety (25-36).  In some cases,  the conjugate-induced 
anti-carbohydrate  antibodies  were  shown  to  have  a  protective  effect  against  the 
bacteria from which they were derived. Many investigators injected these conjugates 
1  Abbrematwns used m this paper Ab, antibody, ADH, adipic acid dlhydrazlde, AH, adlptc hydrazlde, 
BCG, Calmette-Gu~rin bacdlus, BSA, bovine serum albumin  CFA, complete Freund's adjuvant, CNBr, 
cyanogen bromide, EDAC, 1-ethyl-3-(3-dimethylammopropyl)carbodnmlde;  HIB, Haemophdus influenza 
type b; HIB ps, purified HIB capsular polysaccharide, HSA, human serum albumin, Johnson, Johnson- 
Yale strata of HIB; Kd, partition coefficient;  LPS, hpopolysaecharlde,  Mad, Madlgan strata of HIB, PBS, 
phosphate-buffered sahne, Pn 3, pneumococcus  type 3 capsular polysacchande, TNBS trmltrobenzene 
sulfomc acid 
THE JOURNAL OF EXPERIMENTAL MEDICINE • VOLUME 152, 1980  361 362  HAEMOPHILUS INFLUENZAE  POLYSACCHARIDE-PROTEIN CONJUGATES 
in complete Freund's  adjuvant  (CFA)  and/or by the intravenous or intraperitoneal 
routes, factors that limit their applicability for use tn humans. 
In  this  study,  conjugates  of HIB  Ps  and  serum  albumins,  HIB  Ps  and  Ltmulus 
polyphemus  hemocyanin,  and  HIB  Ps  and  diphtheria  toxin  were  prepared.  Their 
composition,  molecular  size,  and  immunogenicity,  both  as  saline  solutions  and  in 
CFA,  were  characterized  in  several  laboratory  animals.  The  effect  of the  carrier 
molecule  upon  the  immunogenicity  of the  HIB  Ps  was  studied  by comparing  the 
serum  anti-HIB  Ps  response  to  conjugates  prepared  with  these  proteins  to  those 
prepared with two polysaccharides: HIB Ps itself and pneumococcus type 3 polysac- 
charide. 
Materials  and Methods 
Chemzcals.  The following reagents were used' Adipic acid dlhydrazide (ADH)  (lot  A8X), 
trinitrobenzene sulfonic acid (TNBS) (lot 8746),  and cyanogen bromide (CNBr) (lot KL23X), 
all  from Eastman  Kodak Co.,  Rochester,  N.  Y.,  1-ethyl-3-(3-dimethylaminopropyl)carbodi- 
imide-HCl (EDAC) (lot  18733) and sodium dodecyl sulfate, both from Bio-Rad Laboratories, 
Richmond, Calif.;  hexadecyhrimethylammonium bromide  (Cetavlon),  NAD (grade AA; lot 
36C01097),  RNAase A  (type II-A: lot  16C-8055),  pronase (protease type VI)  (lot  56C-0914), 
and bovine serum albumin  (ESA), (lot  58C-8040), all  from Sigma Chemical Co, St  Louts, 
Mo.);  human serum albumin  (HSA)  (lot  NC602),  from Cutter  Laboratories,  Inc.,  Berkley, 
Calif.; DNase I (lot D-56M631), from Worthington Biochemical Corp., Freehold, N  J.; CL-4B 
Sepharose (lot  12985), from Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piseataway, 
N. J, brain-heart  infusion, from Difco Laboratories, Detroit,  Mich.)  The HSA was treated 
with activated charcoal (Norit A; Fisher Scientific Co., Pittsburgh, Pa.) as described elsewhere 
(37)  The  diphtheria  toxin  was  prepared  by  Dr.  John  Robinson,  Vanderbih  University, 
Nashville,  Tenn.  (Food  and  Drug  Administration  contract  223-73-12367)  according  to  a 
published  method  (38) The hemocyanin was prepared  from the cell-free  hemolymph of the 
horseshoe crab (L polyphemus) (39) The fluid was centrifuged three umes at  150,000g, for 5 h 
at 4°C  The dark blue pellet was redissolved m phosphate-buffered saline (PBS), pH 7.4, and 
centrifuged at 16,000g, for i h at 4°C, then centrifuged at 150,000g, for 5 h at 4°C  The pellet, 
resuspended after the third uhracentrifugation, was passed through a sterile 0.45-nm membrane, 
(Nalge Co., Nalgene Labware Div, Rochester, N. Y ) and stored at 4°C Acid-cleaned glassware 
and double-distilled pyrogen-free water were used. 
Polysacchandes.  HIB strains  1482, Madigan  (Mad),  Eagen (kindly provided by Dr  Porter 
Anderson and Dr  David H. Smith of the Department of Pediatrics, University of Rochester, 
Rochester, N. Y ), Johnson-Yale (Johnson), and Rab were grown in Levinthal media supple- 
mented with  10 rag/liter of NAD and 0.5 g/liter each of CaCI2, MgSO~, and citric acid. The 
culture was grown at 37°C with high aeration and was stirred up to the late logarithmic-growth 
phase  The  cells  were  harvested  by centrifugation,  and  the  paste  was  suspended  in  1.0% 
Cetavlon, 0.5 M  NaCI (-50 g wet weight of cells/liter)  and stirred vigorously at 37°C for 2 h 
(E. C  Gotschlich. Unpublished observations )  The suspension was centrifuged at  16,000 g for 
2  h  at  4°C,  and  the  pellet  discarded.  The  supernate  was  brought  to  25%  ethanol,  stored 
overnight at 3-8°C, and then centrifuged at  16,000g for 1 h at 4°C  The pellet was discarded, 
and the supernate brought to 70% ethanol and stored overnight at 3-8°C  The precipitate was 
removed by centrifugation at  2,500 g, at  4°C and washed two times with 95% ethanol. The 
precipitate  was  treated  first  with  DNase  I  and  RNAase  A  followed  by  pronase  and  was 
extracted with cold phenol, pH 7.0, to remove residual protein (40-42). The resultant product 
was dialyzed against  0.1  M  CaCI2 and  then  uhracentrifuged  to remove hpopolysaccharlde 
(LPS),  dialyzed  exhaustively  against  double-disnlled  water  at  3-8°C,  and  freeze-dried  as 
described (41). The final yield was ~50 mg of HIB Ps/liter culture fluid  Pneumococcus type 
3 capsular polysaccharide  (Pn  3),  manufactured  for the National  Institutes  of Allergy and 
Infectious Diseases  (NIAID) by the Eli Lilly & Co, Indianapolis, Ind. (lot 812346),  was kindly 
provided by Dr James C. Hill of the NIAID, National Institutes of Health (NIH). This Pn 3 
preparation  contained  50 0%  wt'wt  uronic  acid  and  had  <2.0%  protein  and  nucleic  acids R  SCHNEERSON, O  BARRERA, A  SUTTON,  AND J.  ROBBINS  363 
Eschenchza cob K13 Ps was kindly donated by Dr  Willie Vann, Bureau of Biologics, Food and 
Drug Administration 
Analytzcal Methods  The protein, nucleic acid, moisture, endotoxin (LPS) content of the HIB 
Ps preparations were assayed as described (42-44)  The polysaccharide contents of the HIB Ps 
solutions and of the conjugates were measured by the Bial reaction using an HIB Ps sample 
dried  to  constant weight  over  P205  in vacuo at  37°C  (45) The hydrazide content of the 
derivatized proteins and polysaccharides was estimated by the TNBS method and is expressed 
as mol adipic hydrazide (AH)/mol protein (46, 47) shown as the numerical designation after 
the carrier (e.g.; Johnson-BSA-33). Briefly, 0.5 ml of the ADH standards or of the unknowns 
was added to 0 5 ml of a saturated solution of sodium borate equilibrated at room temperature 
A 0 15-ml aliquot of 3 0% TNBS solution was added to each tube, mixed, and the absorbance 
was  read within 5 mm at  500  nm. The readings obtained with the native protein (usually 
< 10% of the denvatized protein) were subtracted. The sensitivity  of the assay was 5 ×  10  -6 tool 
of ADH  The number of AH residues/mol protein is shown as the numerical designation after 
the carrier. 
Hyperzmmune Antlsera.  Burro and rabbit HIB typing antisera were prepared in our laboratory 
and were  also obtained from  Ms.  Leslie  Wetterlow, Massachusetts Public Health Biologics 
Laboratories, Jamaica Plains, Mass  and Dr. Lucllle Greenwood, Michigan State Public Health 
Laboratories, East Lansing, Mich. (10). 
Serologzc  Serum  HIB  anticapsular antibodies  were  measured  by  a  radiolmmunoassay 
having a sensitivity of 0.03 #g antibody (Ab)/ml and a reproducibility of ±  10% (12). Serum 
complement-dependent  bactericidal antibodies were assayed as described using precolostral calf 
serum as a complement source and the Eagen strain as the target organism (10). Immunodif- 
fusion analysis employed  1.0% agarose in saline under previously described conditions (41). 
Quantitative preeipitin analysis employed 0 2-ml aliquots of the HIB Ps and 0 2 ml of burro 
132 HIB immunoglobulin  (14.1 mg anti-type b Ab/ml). 
HIB PS-Protetn Conjugates.  AH derivatives of BSA, HSA, hemocyanin, and diphtheria toxin 
(collectively designated AH-protein) with varying degrees of derivatizatlon were prepared (47- 
49).  Protein solutions (25 mg/ml) and ADH  (3.45  rag/rag protein) were reacted with three 
different coneentrauons of EDAC (0 1, 0.3, and 0.6 rag/rag protein)  The pH of the reaction 
mixture was  maintained at  4.7  ±  0.2  with  0.1  N  HC!  The  reaction  proceeded  at  room 
temperature for 3 h  and the reaction mixtures were dialyzed at  3-8°C with two changes/d 
against 6 liter of 0 2 M  NaCI  The albumin and Pn 3 polysaccharide derivatives were then 
dialyzed against two 6-liter changes of deionized water and freeze-dried.  The diphtheria toxin 
and hemocyanin derivatives were then dialyzed against two changes/d of PBS, sterile-filtered, 
and stored at 3-8°C. The HIB Ps was activated with CNBr as descrsbed  (12, 49, 50)  Briefly, 
a solution of HIB Ps (5.0 mg/ml), equilibrated at 4°C, was rapidly brought to pH 10.5 with 0.1 
N NaOH.  100 mg/ml CNBr was added to a final concentration of 0.4 mg/mg polysaccharide, 
and the pH maintained at  10.5 for 6 rain. Then the reaction mixture was brought to pH 8 5 
with 0.5 M NaHCO3, and the CNBr-actlvated HIB Ps added to an equal weight of AH-protem 
or Pn 3 (50 mg/ml dissolved in 0 5 M  NaHCO3). The reaction mixture was tumbled gently 
overnight at 3-8°C and then centrifuged at 16,000 g, 4°C for 20 ram. The supernate was passed 
through a CL-4B Sepharose column, 1 5 × 90 cm, that was equihbrated with 0 2 M ammonium 
acetate. The void-volume fractions were pooled, dialyzed against 0.01 M  phosphate-buffered 
0.145  M  NaCI,  pH  7.0,  at  3-8°C, and passed  through  a  045-nm membrane (Nagle Co., 
Nalgene Labware Div.) and stored at 3-8°C. 
Animals.  BALB/c, C57BL/6, and general-purpose mice from the NIH colony, weighing 
-20 g, were injected subcutaneously with saline solutions of the conjugates or of the controls 
Female white albino rabbits, weighing ~ 1.0 kg, were injected with 35/.tg of the Johnson-BSA- 
33 conjugate or with one of the controls emulsified in 3 0 ml of CFA prepared with 1 volume 
of the antigen in PBS, 0.7 volume of Arlacel A (Atlas Chemical Co., Miami, Fla.), 1 4 volumes 
Bayol 92 (Exxon Chemical Co., N  Y ), and  10 mg of dried Calmette-Gu~rin bacillus(BCG)/ 
animal (prepared by Dr. Quentin Myrvik, Bowman Gray College of Medicine, Winston-Salem, 
N  C.) 
Mutagenes~s Assay  Three compounds were assayed for their mutagenic and toxicity potential 
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TA1535,  TA1537,  TA1538,  TA98, and TA100,  were used  with and without mouse liver S-9 
fraction  Undiluted ADH  (500 ~g/plate), Johnson-BSA-33  (68.3/~g/plate)  and BSA-33 (300 
/tg/plate), and  fourfold  diluttons of each showed no toxicity or mutagenicity at the highest 
concentrations tested.  These assays were kindly performed by Dr  E.J.  Lazear, Dtvislon  of 
Mutagenesis  Research, National Center for Toxicological Research, Food and Drug admims- 
tration 
Results 
Charactenzatzon ofHIB Ps-Protem Conjugates.  The molecular sizes of the HIB Ps, the 
AH-protein derivatives, and a  typical HIB Ps-albumin conjugate, Johnson-BSA-33, 
is illustrated in a gel filtration using CL-4B Sepharose (Fig.  1). The AH-BSA showed 
a major symmetrical component with a partition coefficient (Kd) of 0.71  and a small 
peak (-5% of the preparation)  with  a  Kd of 0.60.  The  HIB Ps Johnson  showed  a 
symmetrical peak with a  Kd of 0.33.  Gel filtration of the HIB Ps-protein conjugate, 
Johnson-BSA-33, showed a  new component, with a  larger molecular size than either 
the  HIB Ps or the  AH-protein  derivative, passing  unretarded  through  the column 
(Kd =  0.00) with both protein and polysaccharide. There was second peak containing 
15% of the protein and ~50% of the Hib Ps. 
Not shown are the elution profiles obtained with the same materials passed through 
a  CL-4B Sepharose column equilibrated with  1.0% SDS. The HIB Ps had a  smaller 
molecular size with the SDS solvent yielding a Kd of 0.60. The AH-BSA had a Kd of 
0.70  with  a  slight  trail.  The  mixture of these  two  showed  the  same patterns.  The 
Johnson-BSA-33  conjugate  showed  a  void-volume peak and  a  component  (-40%) 
with  a  Kd  of 0.35.  All  the  fractions  obtained  with  the  HIB  Ps-protein  conjugate 
showed both protein- and pentose-active material. 
Immunodiffusion analysis of the HIB Ps-protein conjugates with antlsera, prepared 
either by intravenous injections of whole formalinized organisms (typing antiserum) 
or by immunization with the Johnson-BSA-33 conjugates in CFA, are shown m  Fig. 
2. With  the HIB typing antisera,  a  single precipitin  line was observed with  HIB Ps 
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FIG  1  Gel filtration through CL-4B Sepharose of.  (A)  HIB  Ps-Johnson-BSA-33 conjugate,  (B) 
AH-BSA-33,  and  (C)  Johnson  HIB  Ps  The  protein  content of the  fractions was  measured  by 
recording the absorbance at  280 nm and  the polysacchande was measured  by the Blal  reaction 
(absorbanee at  670  nm)  (44)  The  fractions 22-28,  contamlng both  protein  and  polysacchande 
components, were pooled, dialyzed against saline, and sterile-filtered for further studies and have 
been designated as Johnson-BSA-33  VI, total volume of column, Vo, void volume 
J 
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FIG  2  Immunodlffus,on  of HIB Ps, HIB Ps-BSA conjugate, E  cob K I3-BSA conjugate, and E 
coh K I3 Ps with antiserum from  rabbit No  2 injected with Johnson-BSA-33 m CFA (center well A) 
(See Table VII) and B132 HIB typing serum (center well B)  For (A) and (B)  well 1 HIB Ps, 0 2 
mg/ml, well 2 Johnson-BSA-33, 0.5 mg/ml; well 3. E  cob KI3-BSA-29  conjugate, well 4  E  cob 
KI3 polysaccharide,  0 5 mg/ml 
and the HIB Ps-BSA conjugate (Fig.  2 B). There was no precipltin reaction with the 
AH-BSA alone or with the E. cob  K13-BSA-33 conjugate. A single precipitin reaction 
was observed with the rabbit antisera raised against the Johnson-BSA-33 conjugate, 
and the HIB Ps, Mad-BSA-33, and E. colt K13-BSA conjugates (Fig. 2A). No reaction 
with the E. colt polysaccharide was observed with either antisera. These observations, 
using gel filtration in aqueous and dissociating solvents and immunodiffusion, indicate 
that the HIB Ps and protein are covalently bound. 
Table I  shows the Kd values for the various HIB Ps preparations. The molecular 
size of the  HIB  Ps conjugates  exceeded  that  of either component.  The ratio of the 
HIB Ps. to protein in the various conjugates varied from  1.15  (Rab-BSA-29)  to 0.16 
(Mad-hemocyanin-29). All the HIB Ps-protein conjugates induced serum anti-type b 
antibodies in general-purpose mice, although a  rigorous analysts of their comparative 
immunogenicity was  not  carried  out.  The  approximate yield of the  conjugate  was 
estimated by comparing the total amount of HIB Ps covalently bound to the protein 
carrier in  the  void-volume fractions to that  in  the  lower-molecular-weight fractions 
after gel filtration through CL-4B Sepharose. 
Two conjugates were prepared using AH derivatives of Pn 3 and HIB Ps (Mad-Pn 
3-33  and  Mad-Mad-12).  Both  polysaccharide-polysacchande conjugates  passed  un- 
retarded through the CL-4B Sepharose column. 
Effect of Dose upon  the Immunogemctty of HIB PS-Protem ConJugate.  In many prehmi- 
nary experiments involving the three mouse strains used in the following experiments, 
only an occasional animal responded to injection of purified HIB Ps (R. Schneerson, 
O.  Barrera, C.  M.  Hardegee, W.  B.  Habig, and J.  B.  Robbins.  Unpublished  obser- 
vations.).  The  immunogenicity  of the  conjugates  was  characterized  by  comparing 366  HAEMOPHILUS INFLUENZAE POLYSACCHARIDE-PROTEIN CONJUGATES 
TABLE  I 
Phystcochemtcal Characterzsttcs of Haemophtlus mfluenzae Type b Conjugates 
Molecular size 
Preparation  HIB Ps-  Approximate 
HIB Ps  protein  yield 
conjugate 
% 
Johnson-BSA-33  0 33  0 77  33 
Mad-BSA-29  0 30  1  0  25 
Rab-BSA-29  0 38  1 15  20 
1482 BSA-33  0 45  0.84  25 
Mad-HSA-17  0 30  0 43  10 
Mad-diphtheria toxin-5  0 30  0 89  25 
Mad-diphtheria toxin-  10  0 30  1.68  21 
Mad-hemocyanm-29  0.30  0.16  26 
Mad-Pn 3-33  0 30  --  18 
Mad-Mad- 12  0 30  --  25 
The molecular size of the HIB Ps and HIB Ps-protem conjugates is characterized by 
their Kd through CL-4B Sepharose (41). The mare component of the conjugates 
passed through the column in the void volume and, therefore, had a Kd of 0.00. The 
ratio of HIB Ps carrier m the conjugates was determined by measurement of the HIB 
Ps using the Bial reaction and the measurement of protein was determined by the 
method of Lowry (41, 42). The yield  of conjugate is expressed as the percent of HIB 
Ps m the conjugate passing unretarded through the CL-4B Sepharose column  The 
number of mol AH resldues/mol protein, as estimated by the TNBS reactton (43), is 
shown as the numerical designation after the carrier 
both the percentage of responding recipients and the level of the response compared 
to the controls. Animals were considered responders if they reacted to immunization 
with serum anti-type b  Ab ~0.15 ~g Ab/ml (estimated to be the protective level in 
humans)  (6-8,  11-13).  The  outbred  general-purpose  mice  were  chosen  for  these 
experiments. In a  representative experiment, the effect of increasing doses of an HIB 
Ps-AH-BSA conjugate, Rab-BSA-29, injected 2  wk  apart,  upon the  level of serum 
anu-type b antibodies 7 d after the last injection was studied (Table II). Doses of 0 01 
and  0.1  ~tg  of the  Rab-BSA-29 conjugate  failed  to  induce a  detectable  antibody 
response. At the  1.0/~g dose, 8/10 animals responded and the geometric mean of the 
responding animals was  1.5  /xg  Ab/ml.  A  slight  increase  in  immunogenicity was 
observed with doses of 2.5  and  10/~g.  With 2.5 ~tg, 9/10 of the  animals responded 
with a geometric mean of 2.3/~g Ab/ml; with 10 ~tg, 9/10 responded with a geometric 
mean of 4.0/~g Ab/ml. Based  upon these experiments and  in consideration of the 
dosage  of HIB  Ps  used  in human infants (6-8,  12,  13,  16),  2.5  /~g  was  chosen  for 
further studies in mice 
Effects of Repeated Injectzons of HIB Ps-Protem  Conjugates m Mtce  Table III shows a 
representative experiment illustrating the effect of repeated immunizations  with Mad- 
hemocyanin-29  upon the level of serum anti-type b A. Groups of 10 mice were injected 
with  2.5 btg of the  HIB  Ps-protein conjugate every 2  wk  for a  total of three doses. 
Groups of l0 mice were  bled 2 wk after the first  immunization and  1 wk after the 
subsequent immunizations and  their sera  assayed  for  HIB  Ps  antibodies  Controls 
were unimmunized animals or animals injected with HIB Ps alone (data not shown) 
that were bled concurrently. There was an immune response after the first immunt- R  SCHNEERSON,  O.  BARRERA,  A  SUTTON,  AND J.  ROBBINS  367 
TABLE  II 
Effect of Dose Upon Immunogematy of HIB Ps-AH-BSA Conjugates 
Micrograms conju- 
gate rejected*  Responders/total 
Anti-type b antibodies 
Geometrm mean of 
responders  Range of all mice 
%  #g/ml 
00l  1/10  10  --  <0 03-0 46 
0.10  0/11  0  --  <0.03 
1 0  8/10  80  1.50  <0 03-8 5 
2.5  9/10  90  2.30  <0.03-31 0 
10.0  9/10  90  4 00  0 05-33 0 
General-purpose mice, weighing --20.0 g, were injected subcutaneously twine (second 
rejection two wk after the first) with varying doses of the HIB Ps-protein conjugate 
Rab-BSA-29.  1 wk after the second injecuon, the mice were bled and their sera 
assayed for HIB Ps Ab by radioimmunoassay (12)  Responders are defined as those 
ammals responding with serum HIB Ps Ab >-0.15 #g/ml serum. Ammals injected 
w~th comparable doses  of HIB Ps or the AH-BSA derivauve alone did not have 
detectable serum Ab. 
* Calculated as micrograms HIB Ps 
TABLE  III 
Effect of the Number of HIB Ps-Protem Conjugate lmmumzat,ons  Upon the Level of 
Serum Antz-Type  b Anttbod~es m Mzce 
Number of mjec-  Uesnonaers/totat 
tmns 
Anu-type b antibodies 
Geometric mean of 
responders  Range of all mice 
%  p.g/ml 
1  5/10  50  1 40  <0 03-4.00 
Control  0/10  0  --  <0.03 
2  8/10  80  2 72  <0.03-17 0 
Control  O/10  0  --  <0,03 
3  8/10  80  3 26  0 04-33.0 
Control  1/10  0  --  <0.03-0.48 
General-purpose mice, weighing ~20 0 g, were rejected subcutaneously with 2 5 #g of 
Mad-hemocyanm-29 conjugate one, two, or three umes (mice that received a total of 
two  or  three  rejections  received  the  subsequent  rejection[s]  at  2-wk  interval[s]). 
Controls were rejected with 2.5 #g of Mad HIB Ps alone. The ammals were bled 14 
d after the first mjecuon and 7 d after the second and third injections and their sera 
assayed for HIB Ps Ab by radiolmmunoassay (12)  Responders are defined as those 
ammals responding w,th serum HIB Ps Ab >--0.15 #g/ml 
zation with the HIB  Ps-protein conjugate  (5/10 responders). The  number  of respond- 
ers  increased  to 8/10  after the second  and  third  injections.  The  geometric  mean  Ab 
level  progressively  increased  from  1.40 #g/ml  after  the  first  injection  to  2.72  #g/ml 
and then to 3.26 #g/ml  after the second and  third immunizations,  respectively. There 
was no detectable serum antibody  response among  both control groups (saline or HIB 
Ps alone). 
Immunogemczty  of  HIB  Ps-Serum  Albumm  Conjugates  m  Three  Mouse  Stratus.  One 
outbred  strain of mice,  general-purpose  mice from  the NIH  colony,  and  two  inbred 
strains, BALB/c  and C57BL/6,  were injected with various HIB  Ps-protein conjugates 
using a  total of two 2.5-#g doses injected subcutaneously  at a  2-wk interval. The  mice 368  HAEMOPHILUS  INFLUENZAE  POLYSACCHARIDE-PROTEIN  CONJUGATES 
were bled  1 wk after the last injection. All three mouse strains showed at least  70% 
responders with geometric mean antibody levels from 0.50 to 2.5 pg/ml;  individual 
levels of responders ranged from 0.16 to 19.0 #g/ml  (Table IV). We could not detect 
any significant difference between the overall type b  antibody response in the three 
mouse strains. Table V shows the anti-type b antibody response induced by the HIB 
Ps-diptheria toxin conjugates. Both lightly and heavily derivatized diphtheria toxin 
preparations formed immunogenic conjugates with 80 and 90% percent of the mice 
responding with geometric mean level of antibodies of 0.72 and 0.80 #g/ml, respec- 
tively. Controls showed only 1/20 responding. 
Bactertc:dal Actwzty of HIB Ps-Protem Conjugates-mduced Ant~bod:es.  In a representative 
experiment, a  group of nine general-purpose mice were injected two times with 2.5 
#g  of Mad-BSA-29  2  wk  apart  and  then  bled  1 wk  after the  last  injection.  The 
bactericidal titer to HIB organisms and  anti-type b  Ab  in  the preimmune animals 
were  1/20 and  <0.03 #g/ml,  respectively. Their postimmune  bactericidal  titers  to 
HIB organisms and anti-type b Ab levels were 1/525 and 2.50 #g/ml, respectively, in 
the immunized group and  1/62 and <0.03, respectively, in the controls (P <  0 001). 
Immunogen:aty of HIB Ps-Capsular Polysacchande Conjugates.  Two different prepara- 
TABLE IV 
Immunogematy of HIB-Ps AH-Albumin  Conjugates m  Three Mouse Stratus 
Anti-type b antibodies 
Mouse  Conjugate rejected  Responders/  Geometric  Range of all 
strain  total  mean of re- 
sponders  m~ce 
%  I.tg/ml 
GPM*  Johnson-BSA-33  7/10  70  0 50  <0 03-1 3 
BALB/c  Mad-HSA- 17  8/10  80  1.50  0.05-3.4 
BALB/c  Rab-BSA-29  7/9  78  1 80  <0.03-19 0 
C57BL/6  Rab-BSA-29  9/l0  90  2.50  0 06-19.0 
Mice were injected subcutaneously with 2 5 #g HIB Ps-albumin conjugate m 0  I ml 
saline twice (second injection 2 wk after the first)  The antmals were bled I wk after 
the last rejection and their serum anti-type b  anubodies assayed  Responders are 
those ammals with a serum ante-type b antibody content ~  15 #g/ml 
* General-purpose mice. 
TABLE g 
Immunogematy of HIB Ps-D:phthena  Toxin Conjugates m BALB/c Mice 
AntHype b antibodies 
Conjugate  Responders/  Geometric 
total  mean of  Range of all 
mice  responders 
%  pg/ml 
Mad-diphtheria toxm-5  8/10  80  0  72  0 06-2 40 
Mad-diphtheria toxin- 18  9/10  90  0 80  0 06-5 05 
Controls  1/10  10  --  <0 03-0 12 
BALB/c mtce were subcutaneously rejected with one of the two diphtheria toxm- 
HIB Ps-protem conjugates or sahne (controls)  twice (second injecuon 2 wk after the 
first) and then bled 7 d after the second rejection. Their sera was assayed for anti-type 
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TABLE  VI 
Effect of Career Pnmmg upon Serum Ants-Type b Anabodtes m Mice Injected w~th HIB Ps-AH-BSA 
Conjugates 
Experiment 1  Experiment 2 
Initml  Geometric  Geometric  Total percentage 
rejection  Responders/  mean of  Responders/total  mean of  of responders 
total  responders*  responders* 
%  % 
BSA  4/10  40  0.56  12/20  60  0.40  53,3 
AH-BSA-20  6/10  60  1,54  10/20  50  0.61  53 3 
AH-BSA-33  7/11  64  0 69  6/20  30  0.28  41 9:1: 
Controls  2/9  23  0.36  2/30  7  0 41  10.3§ 
General-purpose mice were rejected subcutaneously with 2.5/~g of BSA, or the AH-BSA derivatives used 
for preparation of the HIB Ps-protein conjugates, or sahne. 2 wk later, they were rejected with Mad-BSA- 
29 conjugates (2 5/tg HIB Ps-protein conjugate) and then bled  I wk later  Their sera were assayed for 
anti-type b antibodies by radioimmunoassay (12). 
* Expressed as micrograms/milliliter ann-type b antibodies. 
~: P <  0 001 compared to each of the above percentages (53 3%) 
§ P <  0.0l compared to the above percentage (41 9%) 
TABLE  VII 
Serum Ant,-Type b Antzbodzes m Rabb~ts Injected wah HIB Ps-BSA Conjugate with CFA 
Immunogen 
Days after  HIB-Ps-BSA  immumza-  AH-BSA 
tlon  conjugate 
Controls 
HIB Ps  AH-BSA +  HIB Ps 
1"  2  3  4  5  6  7  8  9  10  11  12 
~g db/ml 
0  <0.03  0.06  0.40  0.09  006  007  0.12  <003  010  0.48  <0.03  008 
10  280  320  88  0.05  0.11  0.13  018  0.05  0.90  015  G003  <003 
30*  500  640  140  0.07  0.11  0,17  020  <003  045  0  16  <0.03  0 16 
9  1480  4800  500  0.15  2.30  0.34  0.25  008  1 90  054  0.05  0 18 
17  1480  4600  520  0 10  1 60  0.78  0.23  0.06  3 10  0.35  007  023 
Animals reimmunized with original preparation in incomplete Freund's adjuvant. Young adult female 
rabbits were injected with 35 ~g of Johnson-BSA-33 conjugate dissolved m  1.0 ml of saline, 2 ml of CFA, 
and 5 mg of dried, heat-killed BCG at multiple intradermal sites  They were remjected with the same 
material without the BCG 30 d  later. Controls included the AH-BSA derivattve alone, or the AH-BSA 
derivative mixed with the HIB-Ps, or the HIB Ps alone  The anti-type b anubodies were measured by 
radioimmunoassay (14) 
* Rabbit No 
tions  of  conjugates  formed  by  the  reaction  of  CNBr-activated  HIB  Ps  with  AH 
derivatives of Pn 3  or HIB  Ps itself (Table I) were injected into general purpose  mice 
with doses of 0.5 and  2.5/zg HIB  Ps/conjugate.  The same dose was injected twice into 
10 animals  2  wk apart.  The  mice were  bled  1 wk after the last injection.  There  were 
no responders  detected  in all the experimental  or the control  mice  (saline or HIB  Ps 
alone). 
Effect of Prtmmg  wtth  Carrter  Proteins  upon  Anti-Type  b Anttbo&es  Induced by  HIB  Ps- 
Protem  Conjugates.  Groups  of  10  general-purpose  mice  were  injected  with  2.5  ~g  of 
BSA,  AH-BSA-20  or AH-BSA-33,  or saline.  2  wk  later,  they  were  injected  with  2.5 370  HAEMOPHILUS INFLUENZAE POLYSACCHARIDE-PROTEIN CONJUGATES 
~g of Johnson-BSA-33  conjugate  in  one experiment,  and  Mad-BSA-20  in  another. 
The animals were bled  1 wk later. Table VI shows that a  priming effect, as defined 
by an enhanced  serum anti-type b  A  response after injection  of the conjugate,  was 
induced  by the  lightly  (P <  0.001)  and  heavily AH-derivatized preparations  (P < 
0.01)  and by the native BSA  (P <  0.001).  There was no effect upon the HIB Ps Ab 
response induced by saline injection. 
Immunogemczty of HIB Ps-Protem Con3ugates m Rabb~ts.  Groups of three rabbits each 
were injected each with 35 ~g of Johnson-BSA-33 conjugate emusified in CFA. The 
controls included the HIB-Ps or the AH-BSA-33 derivative alone, or the two physically 
mixed together.  The animals were reinjected  30 d  later with  the same preparations 
emulsified in incomplete Freund's adjuvant.  Table VII shows the serum anti-type b 
Ab at various intervals after the injections. The controls, injected with either HIB Ps, 
the AH-BSA derivative, or both mixed together yielded little or no increase in serum 
anti-type b  Ab. The three rabbits that received the conjugate in CFA reacted w,th a 
1,300-  to 76,000-fold increase in anti-type b Ab with postimmune levels ranging from 
520 to 4,600/tg anti-type b Ab/ml (P<  0.001). 
Not shown are the results of the bactericidal Ab titers of the rabbit sera with the 
HIB strain Eagen. All preimmune sera had low bactericidal antibody titers ranging 
from  1/2  to  1/32.  The  HIB  Ps-AH-BSA conjugate  in  CFA  induced  post-immune 
bactericidal titers of 1/1,024 to 1/8,192, whereas, the controls had levels ranging from 
1/20 to 1/512 (rabbit 7). Absorption of the postimmune sera with the HIB Ps removed 
most or all of the bactericidal activity. 
Discussion 
HIB Ps is a polymer composed of the following repeating subunit' 
3)-/~-D-Ribf-(1 ~  1)-ribitol-5-(PO4 ~  (53). 
There are no carboxylic acids or as-yet-detectable terminal aldehyde moieties to form 
direct covalent linkages with the amino groups of proteins or other potential carriers 
Further,  the phosphodiester bond  linking ribitol  and  ribose is labile at  both  acidic 
and  basic  conditions  and  at  temperatures  higher  than  37 ° .  Accordingly,  we  used 
CNBr  activation  under  previously  described  conditions  to  create  an  electrophilic 
group on the HIB Ps (12, 49, 50). Although this intermediate HIB Ps product reacts 
efficiently to form a  covalent bond with amino groups such as tyramine (12, 50), we 
were  unable  to  form conjugates  with  several  proteins  including  BSA.  It  has  been 
reported that some proteins and other macromolecules require a  spacer to quantita- 
tively bind  to  another  moiety such  as  an  insoluble  carbohydrate  (48).  Of the  six- 
carbon moieties we studied as a spacer, only the ADH consistently provided relatively 
high yields of convalently bound HIB Ps-protein conjugates. Our initial experiments 
indicate  that  ~20  mol  of AH/mol  of carrier  protein  provide  the  most  effective 
substrate for CNBr-activated HIB Ps  The AH derivatizauon procedure caused some 
of the  diphtheria  toxin  and  hemocyanin  to  become  insoluble.  AH  derivatives  of 
bovine  and  human  serum  albumins,  hemocyanin,  diphtheria  toxin,  and  Pn  3, 
prepared by the water-soluble carbodiimide condensation  method, are stable for at 
least 6 mo and may be stored at 3-8°C. The reaction between these AH derivatives 
and the CNBr-activated HIB Ps is completed at pH 8.5 at 4°C in  15 h. We estimate 
that at least 90 percent of the protein is covalently bound to the HIB Ps and that the R  SCHNEERSON, O  BARRERA, A  SUTTON, AND J  ROBBINS  371 
average HIB Ps:protein  ratio of immunogenic conjugates was  0.5-1.5:1.  All  seven 
HIB Ps-protein conjugates with these characteristics had similar immunogenicity in 
three mouse strains.  Not shown were the results obtained with one HIB Ps-protein 
conjugate preparation, Johnson-BSA-33,  that  had  depolymerization of the HIB Ps 
component during the CNBr-activation step. This conjugate had a Kd of  0.45 (smaller 
size than original  HIB Ps)  and  an  8.33  ratio of HIB Ps:BSA.  This conjugate had 
similar  immunogenicity  as  the  other  higher-molecular  weight-preparations.  This 
finding suggests that there may be a wide range of molecular sizes and polysaccharide 
ratios  that  yield  immunogenic  polysaccharide-protein conjugates.  This  method  of 
preparing protein-polysaccharide conjugates has been extended to E. colt K1 and Kla 
capsular  polysaccharides, which  have carboxylic acid  residues  and  do not  contain 
phosphodiester bonds  (41,  54;  and  R.  Schneerson, O.  Barrera, and J.  B.  Robbins. 
Unpublished observations.). 
Our experiments offer some evidence that the HIB Ps has been converted from a 
thymic-independent  to  a  thymic-dependent  immunogen.  This  evidence  may  be 
summarized as follows:  (a) The immunogenicity of the HIB Ps was increased when 
presented as a covalently bound protein-polysaccharide conjugate. The covalent bond 
seems to be necessary because the HIB Ps mixed with negatively charged macromol- 
ecules to form multiple electrostatic interactions, such as with poly-L-lysine, poly-L- 
Lys,Tyr,Ala, or methylated serum albumins, or methylated diphtheria toxin, does not 
invariably induce serum  antibodies after subcutaneous  injection of saline solutions 
into mice or rabbits (41, 54; and R. Schneerson, O. Barrera, C. M. Hardegree, W. B. 
Habig, and J.  B.  Robbins.  Unpublished observations.).  (b)  The immunogenicity of 
the HIB Ps component of the conjugate is related to the carrier molecule. Carrier 
molecules  composed  of thymic-dependent  immunogens  such  as  serum  albumins, 
hemocyanin, and diphtheria toxin, served to enhance the immunogenicity of HIB Ps. 
In contrast, conjugates prepared with the thymic-independent Pn  3 or the HIB Ps 
itself, though of comparatively high molecular size, failed to induce a serum anti-type 
b response. This finding is consistent with studies that show that covalent binding of 
haptens to thymic-independent molecules, such as pneumococcal capsular  polysac- 
charide  type 3,  confer the  immunogenic properties of the  carrier molecule to  the 
antigenic components of the conjugate (55, 56). Although a negative finding, such as 
the lack of immunogenicity, is difficult to interpret, the experiments with both the Pn 
3-HIB  Ps  and  the  HIB  Ps-HIB  conjugates  suggest  that  the  molecular size  of the 
conjugates, shown to be directly related to the immunogenicity of polysaccharides, 
may not be a critical variable of the immunogenicity of these hybrid molecules (40, 
42,  43).  Both  of these  polysaccharide-polysaccharide conjugates  had  considerably 
higher molecular-sizing characteristics than  the parent  molecule, yet they failed to 
induce serum  antibodies.  (c)  Reinjection  of HIB-Ps-protein conjugates  induced an 
increase in both the number of responders and  in the total level of anti-type b  Ab 
(booster  effect)  (57-59).  (d)  Carrier  priming,  induced  by  the  BSA  and  AH-BSA 
derivatives, resulted in an enhanced serum anti-type b  antibody response to initial 
immunization with the conjugate (59-62). Further experiments to study the cellular 
basis  for the  enhanced  immungenicity  of the  HIB  Ps-protein  conjugates  and  the 
molecular characteristics of the serum antibodies are planned (60, 61). 
In  preliminary experiments, the  HIB  Ps-protein conjugate induced an  eightfold 
increase in anti-type b  antibodies with bactericidal activity in young adult primates 372  HAEMOPHILUS  INFLUENZAE  POLYSACCHARIDE-PROTEIN CONJUGATES 
(Macacafasctcularts).  Injection of the purified HIB Ps into this, as well as other, primate 
species yielded a  lesser serum anti-type b  antibody response (62;  L.  Martin  and  P 
Anderson. Unpublished data.). Furthermore, the E. cob K1- and K13-protein conju- 
gates  induced  serum  anticapsular  polysaccharide  antibodies  in  rabbits  and  rats, 
respectively. Experiments are planned to study the comparative immunogenicity of 
these capsular polysaccharides bonded to different carriers as well as to characterize 
the reactivity to the carrier protein (60, 61). 
The serum antibodies induced by the HIB Ps-protein conjugates exerted a comple- 
ment-dependent bactericidal activity that has been associated with immunity against 
HIB type b  diseases (1-12). The ADH, the AH derivative of BSA, and the HIB Ps- 
BSA conjugate showed no toxicity or mutagenic activity using an in vitro bacterial 
assay system (51, 52). Toxicity tests showed that the lethal dose was > 100 mg/22- to 
25-g laboratory mouse (63). Accordingly, this synthetic approach to prepare capsular 
polysaecharide-protein conjugates may be considered for clinical investigation. 
Summary 
A method is presented for covalently bonding Haemoph~lus  mfluenzae type b capsular 
polysaecharide (HIB Ps) to several proteins. The method is efficient and relies upon 
the use of adipic dihydrazide as a spacer between the capsular polysaccharide and the 
carrier protein.  In contrast  to the  poor immunogenicity of the purified HIB  Ps  in 
mice and rabbits, the HIB Ps-protein conjugates induced serum anti-type b antibodies 
having bactericidal activity at  levels shown  to be protective in  humans  when  low 
doses were injected subcutaneously in a saline solution. The antibody response in mice 
was related to the dose of the conjugates, increased with the number of injections, and 
could be primed by the previous injection of the carrier protein. The HIB Ps-protein 
conjugates were immunogenic in three different mouse strains. The importance of the 
carrier molecule for the enhanced immunogenicity of the HIB Ps-protein conjugates 
was  shown  by the failure of HIB Ps hybrids prepared with either the homologous 
polysaccharide or pneumococcus type 3 polysaccharide to induce antibodies in mice 
Rabbits injected with the HIB Ps-protein conjugates emulsified in Freund's adjuvant 
produced high levels of serum anti-type b  antibodies which  induced a  bactericidal 
effect upon H.  mfluenzae type b organisms. It is proposed that the HIB Ps component 
of the polysaccharide protein conjugates has been converted to a thymic-dependent 
immunogen. This method may be used to prepare protein-polysaccharide conjugates 
with HIB Ps and other polysaccharides to be considered for human use. 
We gratefully acknowledge the suggestion by Dr. Melr Wilchek, Weizmann Institute of Science, 
Rehovot, Israel, to use the adipic dihydrazide as a spacer molecule 
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